Condition
Recurrent Desmoplastic Small Round Cell Tumor
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04616560Phase 1Recruiting
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
NCT04530487Phase 2Terminated
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
NCT04213794Early Phase 1Terminated
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
Showing all 3 trials